-
1Academic Journal
Source: Наука и здравоохранение. :67-76
Subject Terms: қауп факторлары, стенттеу, стентирование, stenting, факторы риска, интракраниальды стеноз, 3. Good health, атеросклеротикалық зақымдануы, атеросклеротическое поражение, экстракраниальный стеноз, интракраниальный стеноз, intracranial stenosis, risk factors, atherosclerotic lesions, extracranial stenosis, экстракраниальды стеноз
-
2Academic Journal
Authors: E. V. Gerasimova, T. V. Popkova, I. G. Kirillova, D. A. Gerasimova, E. L. Nasonov, Е. В. Герасимова, Т. В. Попкова, И. Г. Кириллова, Д. А. Герасимова, Е. Л. Насонов
Contributors: Настоящее исследование выполнено в рамках фундаментальной темы № 1021051402790-6 «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний».
Source: Rheumatology Science and Practice; Vol 62, No 1 (2024); 81-89 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 81-89 ; 1995-4492 ; 1995-4484
Subject Terms: атеросклеротическое поражение сосудов, tocilizumab, traditional risk factors, dyslipidemia, total cardiovascular risk, SCORE, atherosclerotic vascular disease, тоцилизумаб, традиционные факторы риска, дислипидемия, суммарный сердечно-сосудистый риск
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3516/2351; England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ. 2018;23(361):1036. doi:10.1136/bmj.k1036; Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: The Spanish cohort of the COMORA study. Reumatol Clin (Engl Ed). 2019;15(2):102-108. doi:10.1016/j.reuma.2017.06.002; Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.:ГЭОТАР-Медиа;2020.; Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2015;10(2):0117952. doi:10.1371/journal.pone.0117952; Удачкина ЕВ, Новикова ДС, Попкова ТВ, Насонов ЕЛ. Роль интерлейкина 6 в развитии атеросклероза при ревматоидном артрите. Современная ревматология. 2013;7(3):25-32. doi:10.14412/1996-7012-2013-7; Eltoft A, Arntzen KA, Wilsgaard T, Mathiesen EB, Johnsen SH. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study. Atherosclerosis. 2018;271:1-8.; Lubrano V, Gabriele M, Puntoni MR, Longo V, Pucci L. Relationship among IL-6, LDL cholesterol and lipid peroxidation. Cell Mol Biol Lett. 2015;20(2):310-322. doi:10.1515/cmble-2015-0020; Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, et al.; CATCH group. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology (Oxford). 2017;56(5):768-776. doi:10.1093/rheumatology/kew474; Насонов ЕЛ, Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12. doi:10.26442/terarkh20189054-12; McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702. doi:10.1136/annrheumdis-2013-204345; Castagné B, Viprey M, Martin K, Schott A-M, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14(8):0220178. doi:10.1371/journal.pone.0220178; Jones G, Wallace T, McIntosh MJ, Brockwell L, Gómez-Reino JJ, Sebba A. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexateand biologic-naive or free of methotrexate for 6 months: The AMBITION study. J Rheumatol. 2017;44(2):142-146. doi:10.3899/jrheum.160287; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi:10.14412/1995-4484-2017-590-599; Комитет экспертов РКО. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6 Прил. 2.):46.; Герасимова ЕВ, Попкова ТВ, Мартынова АВ, Кириллова ИГ, Маркелова ЕИ, Семашко АС, и др. Динамика традиционных модифицируемых факторов риска, суммарного сердечно-сосудистого риска и структурных изменений сонных артерий у больных ревматоидным артритом на фоне длительной терапии ингибитором рецепторов интерлейкина-6. Научно-практическая ревматология. 2021;59(1):84-92. doi:10.47360/1995-4484-2021-84-92; Попкова ТВ, Новикова ДС, Панасюк ЕЮ, Авдеева АС, Удачкина ЕВ, Александрова ЕН, и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;84(5):9-18.; Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1806-1812. doi:10.1136/annrheumdis-2015-207872; Toussirot E. The Interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020;10(3):107. doi:10.3390/metabo10030107; Choi I, Sagawa A, Lee E, Lee EB, Song YW. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: A retrospective cohort study. J Korean Med Sci. 2020;35(22):e55. doi:10.3346/jkms.2020.35.e155; Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646. doi:10.1002/jcsm.12189; Wada E, Tanihata J, Iwamura A, Takeda S, Hayashi YK, Matsuda R. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice. Skelet Muscle. 2017;7(1):23. doi:10.1186/s13395-017-0140-z; Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, et al. Tocilizumab, a proposed therapy for the cachexia of interleukin 6-expressing lung cancer. PLoS One. 2014;9(7):e102436. doi:10.1371/journal.pone.0102436; Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980. doi:10.1002/art.23940; Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: A post hoc analysis. Rheumatol Ther. 2017;4(1):133-149. doi:10.1007/s40744-016-0049-8; Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci. 2019;20(18):4633. doi:10.3390/ijms20184633; Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:141. doi:10.1186/ar3455; IL6R Genetics Consortium Emerging Risk Factors Collaboration; Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379(9822):1205-1213. doi:10.1016/S0140-6736(11)61931-4; Navarro G, Taroumian S, Barroso N, Duan L, Furs D. Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014;43(4):458-469. doi:10.1016/j.semarthrit.2013.08.001; Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DP. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1437-1449. doi:10.1002/art.40892; Abeles AM, Pillinge MH. Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy? Arthritis Rheumatol. 2006;54(2):393-407. doi:10.1002/art.21521; Halacoglu J, Shea LA. Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis. J Cardiovasc Transl Res. 2020;13:878-90. doi:10.1007/s12265-020-09964-9; Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26(1):88-96. doi:10.1016/j.smim.2014.01.009; Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, et al. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment. Mediators Inflamm. 2018;2018:2453265. doi:10.1155/2018/2453265; Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A multi-database cohort study. Arthritis Rheumatol. 2017;69(6):1154-1164. doi:10.1002/art.40084; Ferraz-Amaro I, Hernández-Hernández MV, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, Machado JD, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res. 2019;51(3):200-209. doi:10.1055/a-0833-4627; Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, DallingaThie GM, Levels JH, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229(1):174-181. doi:10.1016/j.atherosclerosis.2013.04.031; Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res. 2017;183:87-103. doi:10.1016/j.trsl.2016.12.003; Bacchiega BC, Bacchiega AB, Usnayo MJG, Bedirian R, Singh G, Pinheiro G. Interleukin 6 inhibition and coronary artery disease in a high-risk population: A prospective community-based clinical study. J Am Heart Assoc. 2017;6(3):e005038. doi:10.1161/JAHA.116.005038; Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H, Tsoumani M, et al. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol. 2019;108(10):1093-1101. doi:10.1007/s00392-019-01443-9; Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as An open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169-2171. doi:10.3899/jrheum.110340; Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi:10.1186/s13075-015-0559-8; Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67(2):372-380. doi:10.1002/art.38920; Okazaki S, Sakaguchi M, Miwa K, Furukado S, Yamagami H, Yagita Y, et al. Association of interleukin-6 with the progression of carotid atherosclerosis: A 9-year follow-up study. Stroke. 2014;45(10):2924-2929. doi:10.1161/STROKEAHA.114.005991; Puz P, Lasek-Bal A. Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression. Atherosclerosis. 2017;263:97-103. doi:10.1016/j.atherosclerosis.2017.06.008; Pauli N, Puchałowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, et al. Associations between IL-6 and echoparameters in patients with early onset coronary artery disease. Diagnostics (Basel). 2019;9(4):189. doi:10.3390/diagnostics9040189; Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813-1818. doi:10.1136/annrheumdis-2015-207870; Grange S, Schmitt C, Ganeshalingam K, Choy EH. Tocilizumab did not significantly increase serum cholesterol levels in healthy subjects. Rheumatology (Oxford). 2014;53:95-96. doi:10.1093/rheumatology/keu101.023; Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, et al. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clin Exp Rheumatol. 2022;40(9):1657-1665. doi:10.55563/clinexprheumatol/f7ff6q; Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, et al. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2021;39(2):319-328. doi:10.55563/clinexprheumatol/3qdgi1; Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195-199. doi:10.1177/1759720X18798462; Gale S, Trinh H, Tuckwell K, Collinson N, Stone JH, Sarsour K, et al. Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: Analyses of tocilizumab clinical trials and claims data. Rheumatol Ther. 2019;6(1):77-88. doi:10.1007/s40744-019-0139-5
-
3Academic Journal
Authors: Yu. Yu. Gridneva, A. I. Chesnikova, A. V. Khripun, V. A. Safronenko, E. V. Pashchenko, Ю. Ю. Гриднева, А. И. Чесникова, А. В. Хрипун, В. А. Сафроненко, Е. В. Пащенко
Source: Medical Herald of the South of Russia; Том 15, № 3 (2024); 55-61 ; Медицинский вестник Юга России; Том 15, № 3 (2024); 55-61 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2024-15-3
Subject Terms: чрескожное коронарное вмешательство, subclinical and manifest hypothyroidism, atherosclerotic lesions of the coronary arteries, percutaneous coronary intervention, субклинический и манифестный гипотиреоз, атеросклеротическое поражение коронарных артерий
File Description: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/2013/1048; Izkhakov E, Zahler D, Rozenfeld KL, Ravid D, Banai S, et al. Unknown subclinical hypothyroidism and in-hospital outcomes and short- and long-term all-cause mortality among ST segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Clin Med. 2020; 9(12):3829. https://doi.org/10.3390/jcm9123829; Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005375. https://doi.org/10.1161/circoutcomes.118.005375; Корзухин А.Ю., Юлдошев Д.Р., Трошина А.А., Хурамшина Л.Р., Гузарик В.Н., и др. Инфаркт миокарда 2-го типа: диагностические и терапевтические трудности в современной кардиологии. Комплексные проблемы сердечнососудистых заболеваний. 2023;12(3):84-97. https://doi.org/10.17802/2306-1278-2023-12-3-84-97; Коробка В.Л., Хрипун А.В., Малеванный М.В., Куликовских Я.В. Ближайшие и среднеотдаленные результаты чрескожного коронарного вмешательства с имплантацией биорезорбируемых стентирующих каркасов при остром инфаркте миокарда с подъемом сегмента ST. Эндоваскулярная хирургия. 2015;2(1–2):58–68.; Razvi S, Leng O, Jabbar A, Bano A, Ingoe L, Addison C, et al. Sample Timing, Diagnosis of Subclinical Thyroid Dysfunction and Mortality in Acute Myocardial Infarction: ThyrAMI1 Study. J Clin Endocrinol Metab. 2020;105(4):dgz143. https://doi.org/10.1210/clinem/dgz143. PMID: 31769839.; Zghebi SS, Rutter MK, Sun LY, Ullah W, Rashid M, et al. Comorbidity clusters and in-hospital outcomes in patients admitted with acute myocardial infarction in the USA: A national population-based study. PLoS One. 2023;18(10):e0293314. https://doi.org/10.1371/journal.pone.0293314; Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–534. https://doi.org/10.1001/archinte.160.4.526; Eagan D, Spencer-Bonilla G, Maraka S, Aggarwal M, Singh Ospina N. Management of Hypothyroidism in Patients with Acute Myocardial Infarction. Medicina (Kaunas). 2020;56(5):214. https://doi.org/10.3390/medicina56050214; Рахман М.А., Виджярагхаван Г., Анкудинов А.С., Калягин А.Н. Состояние коронарного русла и оценка роли заместительной гормональной терапии у пациентов с ишемической болезнью сердца на фоне первичного манифестного гипотиреоза. Кардиология. 2020;60(9):76-83. https://doi.org/10.18087/cardio.2020.9.n1029; Драпкина О.М., Гегенава Б.Б., Моргунова Т.Б., Фадеев В.В. Влияние гипотиреоза на сердечно-сосудистую систему. Эндокринология: новости, мнения, обучение. 2016;2(15):21–30. EDN: WHOUSX.; Khan R, Zarak MS, Munir U, Ahmed K, Ullah A. Thrombolysis in Myocardial Infarction (TIMI) risk score assessment for complications in acute anterior wall ST elevation myocardial infarction. Cureus. 2020; 12(6): e8646. https://doi.org/10.7759/cureus.8646; Corona G, Croce L, Sparano C, Petrone L, Sforza A, et al. Thyroid and heart, a clinically relevant relationship. J Endocrinol Invest. 2021;44(12):2535–2544. https://doi.org/10.1007/s40618-021-01590-9; Ning Y, Cheng YJ, Liu LJ, Sara JD, Cao ZY, et al. What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Medicine. 2017; 15(1): 21. https://doi.org/10.1186/s12916-017-0777-9; Liu D, Jiang F, Shan Z, Wang B, Wang J, et al. A cross-sectional survey of relationship between serum TSH level and blood pressure. J Hum Hypertens. 2010;24(2):134-138. https://doi.org/10.1038/jhh.2009.44; Гриднева Ю.Ю., Чесникова А.И., Сафроненко В.А., Едленко Е.В., Затлоукал М.Ю. Частота встречаемости и клиническое значение впервые выявленного гипотиреоза у пациентов с инфарктом миокарда с подъемом сегмента ST. Терапия. 2024;10(4):82–90. https://doi.org/10.18565/therapy.2024.4.82-90; Gluvic ZM, Zafirovic SS, Obradovic MM, Sudar-Milovanovic EM, Rizzo M, Isenovic ER. Hypothyroidism and risk of cardiovascular disease. Curr Pharm Des. 2022;28(25):2065–2072. https://doi.org/10.2174/1381612828666220620160516; https://www.medicalherald.ru/jour/article/view/2013
-
4Academic Journal
Source: Госпитальная медицина: наука и практика. 4:5-9
Subject Terms: осложнения стентирования МАГ, диссекция сонной артерии, атеросклеротическое поражение МАГ, 3. Good health, разрыв сонной артерии
-
5Academic Journal
Source: Хирургия. Восточная Европа. :21-29
Subject Terms: транскутанное напряжение кислорода, 03 medical and health sciences, chronic ischemia of the lower extremities, 0302 clinical medicine, атеросклеротическое поражение, deep femoral-popliteal segment, хроническая ишемия нижних конечностей, глубокий бедренно-подколенный сегмент, transcutaneous oxygen tension, atherosclerotic lesion, оcclusive-stenotic lesion of the femoral-foot segment, 3. Good health, окклюзионно-стенотическое поражение бедренно-стопного сегмента
-
6
-
7Academic Journal
Authors: E. V. Gerasimova, T. V. Popkova, A. V. Martynova, I. G. Kirillova, E. I. Markelova, A. S. Semashko, A. M. Lila, E. L. Nasonov, Е. В. Герасимова, Т. В. Попкова, А. В. Мартынова, И. Г. Кириллова, Е. И. Маркелова, А. С. Семашко, А. М. Лила, Е. Л. Насонов
Contributors: Работа выполнена за счет средств бюджетного финансирования на выполнение государственного задания по фундаментальной научной теме «Разработка методов персонифицированной терапии ревматических заболеваний с коморбидной патологией» № АААА-А19-119021190151-3
Source: Rheumatology Science and Practice; Vol 59, No 1 (2021); 84-92 ; Научно-практическая ревматология; Vol 59, No 1 (2021); 84-92 ; 1995-4492 ; 1995-4484
Subject Terms: атеросклеротическое поражение сосудов, tocilizumab, traditional risk factors, dyslipidemia, total cardiovascular risk, SCORE, atherosclerotic vascular disease, тоцилизумаб, традиционные факторы риска, дислипидемия, суммарный сердечно-сосудистый риск
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2994/2063; Ревматология. Российские клинические рекомендации. Под ред. ЕЛ Насонова. М.: ГЭОТАР-Медиа; 2020:448.; Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: The Spanish cohort of the COMORA study. Reumatol Clin. 2019;15(2):102−108. doi:10.1016/j.reuma.2017.06.002; Попкова ТВ, Новикова ДС. Кардиоваскулярная патология у больных ревматоидным артритом. В кн.: Ревматология. Российские клинические рекомендации. М.: ГЭОТАР-Медиа; 2020:321−340.; Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524−1529. doi:10.1136/annrheumdis-2011-200726; Schieir O, Tosevski C, Glazier R, Hogg-Johnson S, Badley EM. Incident myocardial infarction associated with major types of arthritis in the general population: A systematic review and meta-analysis. Ann Rheum Dis. 2017;76:1396−1404. doi:10.1136/annrheumdis-2016-210275; Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: Lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461−474. doi:10.1038/s41584-019-0256-0; Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study. Arthritis Rheum. 2008;58(8):2268−2274. doi:10.1002/art.23650; Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013;56(2-3):267−286. doi:10.1007/s12026-013-8398-7; Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: Altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44(3):345−352. doi:10.1016/j.semarthrit.2014.06.006; Barbarroja N, Perez-Sancherz C, Ouiz-Limon P. Anticyclic citrullinsted protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34:2706−2716. doi:10.1161/ATVBAHA.114.304475; Hamzic-Mehmedbasic A. Inflammatory cytokines as risk factors for mortality after acute cardiac events. Med Arch. 2016;70(4):252−255. doi:10.5455/medarh.2016.70.252-255; Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler Thromb Vasc Biol. 2019;39(8):1510−1519. doi:10.1161/ATVBAHA.119.311998; Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: Is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390−400. doi:10.1038/nrrheum.2015.40; Su D, Li Z, Li X, Chen Y, Zhang Y, Ding D, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm. 2013:726178. doi:10.1155/2013/726178; Wang XH, Liu SQ, Wang YL, Jin Y. Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res. 2014;13(2):4260−4266. doi:10.4238/2014.June.9.11; Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, et al. HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis. 2015;241:55−61. doi:10.1016/j.atherosclerosis.2015.04.811; AlBadri A, Lai K, Wei J, Landes S, Mehta PK, Li Q, et al. Inflammatory biomarkers as predictors of heart failure in women with-out obstructive coronary artery disease: A report from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE). PLoS One. 2017;12(5):e0177684. doi:10.1371/journal.pone.0177684; Barra L, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, et al. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology. 2017;56(5):768−776. doi:10.1093/rheumatology/kew474; McInnes IB, Thompson L, Giles J, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694−702. doi:10.1136/annrheumdis-2013-204345; Castagné B, Viprey M, Martin K, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14(8):e0220178. doi:10.1371/journal.pone.0220178; Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449−1455. doi:10.1002/art.39098; Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48−54. doi:10.1136/annrheumdis-2017-211735; Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2015;17;10(2):e0117952. doi:10.1371/journal.pone.0117952; Панафидина ТА, Кондратьева ЛВ, Герасимова ЕВ, Новико ва ДС, Попкова ТВ. Коморбидность при ревматоидном артрите. Научно-практическая ревматология. 2014;52(3):283–289. doi:10.14412/1995-4484-2014-283-289; Erum U, Ahsan T, Khowaja D. Lipid abnormalities in patients with rheumatoid arthritis. Pak J Med Sci. 2017;33(1):227−230. doi:10.12669/pjms.331.11699; Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, et al. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: A multinational cross-sectional study. Clin Rheumatol. 2018;37(9):2331−2340. doi:10.1007/s10067-018-4113-3; Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987−997. doi:10.1016/S0140-6736(08)60453-5; Schiff MH, Kremer J, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi:10.1186/ar3455; Попкова ТВ, Новикова ДС, Панасюк ЕЮ, Авдеева АС, Удачкина ЕВ, Александрова ЕН, и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;84(5):9−18.; Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: A systematic review and meta-analysis. Arthritis Rheumatol. 2015;67(1):117−127. doi:10.1002/art.38894; Lee JS, Chapman MJ, Piraino P, Lamerz J, Schindler T, Cutler P, et al. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab. Proteomics Clin Appl. 2016;10(2):183−194. doi:10.1002/prca.201500036; Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: Implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71−80. doi:10.1016/j.semarthrit.2016.03.004; Sarwar N, Butterworth A, Freitag D, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–1213. doi:10.1016/S0140-6736(11)61931-4; Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: A post hoc analysis. Rheumatology and Therapy. 2016;4(1):133–149. doi:10.1007/s40744-016-0049-8; Ferraz-Amaro I, Hernández-Hernández M, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, Machado JD, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab. 2019;51(3):200−209. doi:10.1055/a-0833-4627; Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639−646. doi:10.1002/jcsm.12189; Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab. PLoS One. 2015;10(6):e0130709. doi:10.1371/journal.pone.0130709; Mackey RH, Kuller LH, Moreland LW. Inflammatory joint diseases and atherosclerosis: Time to look beyond the ‘lipid paradox’. Curr Opin Lipidol. 2019;30(4):342−349. doi:10.1097/MOL.0000000000000620; Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: The immune system and atherogenesis: lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005;46:389−403. doi:10.1194/jlr.R400017-JLR200; Wang X, Liao D, Bharadwaj U, Li M, Yao Q, Chen C. C-reactive protein inhibits cholesterol efflux from human macrophagederived foam cells. Arterioscler Thromb Vasc Biol. 2008;28:519−526. doi:10.1161/ATVBAHA.107.159467; Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is inter-leukin-6 the link? Atherosclerosis. 2000;148:209–214. doi:10.1016/S0021-9150(99)00463-3; Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215−225. doi:10.1016/j.autrev.2017.10.013; Shahbaz SK, Sadeghi M, Koushki K, Penson PE, Sahebkar A. Regulatory T cells: Possible mediators for the anti-inflammatory action of statins. Pharmacol Res. 2019;149:104469. doi:10.1016/j.phrs.2019.104469; Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;(3):CD008226. doi:10.1002/14651858.CD008226.pub3; Новикова ДС, Попкова ТВ, Насонов ЕЛ. Артериальная гипертензия при ревматоидном артрите. Научно-практическая ревматология. 2011;50(3):52−68. doi: http://dx.doi.org/10.14412/1995-4484-2011-574; Мясоедова EE. Распространенность и факторы риска артериальной гипертензии при ревматоидном артрите. Научно-практическая ревматология. 2012;50(2):31−34. doi:10.14412/1995-4484-2012-1270; Taylor EB, Wolf VL, Dent E, Ryan MJ. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol. 2019;176(12):1897−1913. doi:10.1111/bph.14604; Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290(3):H935–H940. doi:10.1152/ajpheart.00708.2005; Hashmat S, Rudemiller N, Lund H, Abais-Battad JM, Van Why S, Mattson DL. Interleukin-6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats. Am J Physiol Renal Physiol. 2016;311(3):F555–F561. doi:10.1152/ajprenal.00594.2015; Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014;16(6):504. doi:10.1186/s13075-014-0504-2; Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the risk for cardiovascular disease: A direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res. 2019;71(8):1004−1018. doi:10.1002/acr.23737; Hsieh MJ, Lee CH, Tsai M, Kao CF, Lan WC, Huang YT, et al. Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: A national cohort study. Can J Cardiol. 2020;15:S0828-282X(20)30035-0. doi:10.1016/j.cjca.2020.01.003; Abdelrahman AM, Suleimani YM, Ashique M, Manoj P, Ali BH. Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. Biomed Pharmacother. 2018;105:182−186. doi:10.1016/j.biopha.2018.05.118; Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther. 2010;87(4):396−398. doi:10.1038/clpt.2010.1; Younis S, Rosner I, Rimar D, Boulman N, Rozenbaum M, Odeh M, et al. Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis. J Clin Rheumatol. 2013;19(1):48−49. doi:10.1097/RHU.0b013e31827cdda7; Choi I, Sagawa A, Lee E, Song WY. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: A retrospective cohort study. J Korean Med Sci. 2020;35(22):e155. doi:10.3346/jkms.2020.35.e155; Ji C, Chen X, Gao C, Jiao L, Wang J, Xu G, et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J Bioenerg Biomembr. 2011;43(4):367−375. doi:10.1007/s10863-011-9361-8; Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macro-phages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol. 2014;15(5):423−430. doi:10.1038/ni.2865; Chen D, Chen Y, Hsieh T, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi:10.1186/s13075-015-0559-8; Gotsman I, Stabholz A, Planer D, Pugatsch T, Lapidus L, Novikov Y, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: Indicators of an active inflammatory burden? Isr Med Assoc J. 2008;10(7):494−498.; Cheng HF, Feng Y, Jiang D, Tao KY, Kong MJ. Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury. Asian Pac J Trop Med. 2015;8(1):48−52. doi:10.1016/ S1995-7645(14)60186-3; Zhao L, Cheng G, Jin R, Afzal MR, Samanta A, Xuan YT, et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ Res. 2016;118(12):1918−1929. doi:10.1161/CIRCRESAHA.116.308688; Wang C, Li Q, Yang H, Gao C, Du Q, Zhang C, et al. MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease. J Cell Physiol. 2020;235(11):8283−8292. doi:10.1002/jcp.29485; Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 2014;35(9):540−543. doi:10.1093/eurheartj/eht398; Pauli N, Puchałowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, et al. Associations between IL-6 and echo-parameters in patients with early onset coronary artery disease. Diagnostics (Basel). 2019;9(4):E189. doi:10.3390/diagnostics9040189; Bories GFP, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett. 2017;591(19):3042−3060. doi:10.1002/1873-3468.12786
-
8Academic Journal
-
9Academic Journal
Authors: Savchuk, K. S., Ryabova, L. V., Sosnovskikh, I. V., Савчук, К. С., Рябова, Л. B., Сосновских, И. В.
Subject Terms: DIABETES MELLITUS TYPE 2, DIABETIC NEPHROPATHY, ARTERIAL SCLEROTIC AFFECTION OF LOWER LIMBS, RED CELL DISTRIBUTION WIDTH, CORONARY ARTERY DISEASE, САХАРНЫЙ ДИАБЕТ 2 ТИПА, ДИАБЕТИЧЕСКАЯ НЕФРОПАТИЯ, АТЕРОСКЛЕРОТИЧЕСКОЕ ПОРАЖЕНИЕ АРТЕРИЙ НИЖНИХ КОНЕЧНОСТЕЙ, КОЭФФИЦИЕНТ АНИЗОТРОПИИ ЭРИТРОЦИТОВ, ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА
File Description: application/pdf
Relation: Уральский медицинский журнал. 2019. Т. 169, № 1.; http://elib.usma.ru/handle/usma/10906
Availability: http://elib.usma.ru/handle/usma/10906
-
10Academic Journal
Subject Terms: diabetes mellitus type 2, атеросклеротическое поражение артерий нижних конечностей, диабетическая нефропатия, diabetic nephropathy, ишемическая болезнь сердца, red cell distribution width, сахарный диабет 2 типа, коэффициент анизотропии эритроцитов, arterial sclerotic affection of lower limbs, coronary artery disease, 3. Good health
-
11Academic Journal
Authors: Люлька, Олександр Миколайович, Ляховський, Віталій Іванович, Нємченко, Іван Іванович, Пузирьов, Гай Сергійович, Сапун, Леонід Вікторович, Люлька, Александр Николаевич, Ляховский, Виталий Иванович, Немченко, Иван Иванович, Пузырев, Гай Сергеевич, Сапун, Леонид Викторович, Liulka, O. M., Liakhovskyi, V. I., Niemchenko, I. I., Puzyrov, G. S., Sapun, L. V.
Subject Terms: атеросклеротичне ураження, артерії нижніх кінцівок, реконструктивні операції, ускладнення, атеросклеротическое поражение, артерии нижних конечностей, реконструктивные операции, осложнения, atherosclerotic lesion, arteries of the lower extremities, reconstructive surgery, complications
File Description: application/pdf
Relation: Вiсник проблем бiологiї i медицини. – 2018. - №2. – С. 36-40.; Особливості проведення реконструктивних операцій при атеросклеротичному ураженні артерій нижніх кінцівок / О. М. Люлька, В. І. Ляховський, І. І. Нємченко [та ін.] // Вiсник проблем бiологiї i медицини. – 2018. – Вип. 2 (144). – С. 36–40.; https://repository.pdmu.edu.ua/handle/123456789/8685
Availability: https://repository.pdmu.edu.ua/handle/123456789/8685
-
12Academic Journal
Authors: E. V. Gerasimova, T. V. Popkova, D. S. Novikova, L. B. Kruglyi, O. A. Fomicheva, Yu. A. Karpov, E. L. Nasonov, Е. В. Герасимова, Т. В. Попкова, Д. С. Новикова, Л. Б. Круглый, О. А. Фомичева, Ю. А. Карпов, Е. Л. Насонов
Source: Rheumatology Science and Practice; Vol 55, No 6 (2017); 628-633 ; Научно-практическая ревматология; Vol 55, No 6 (2017); 628-633 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20176
Subject Terms: атеросклеротическое поражение сосудов, coronary artery stenosis, traditional risk factors, atherosclerotic vascular lesions, стеноз коронарных артерий, традиционные факторы риска
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2466/1636; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-media; 2008. P. 290-331].; Yazdanyar A, Wasko MC, Kraemer KL, Ward MM. Perioperative all-cause mortality and cardiovascular events in patients with rheumatoid arthritis: comparison with unaffected controls and persons with diabetes mellitus. Arthritis Rheum. 2012 Aug;64(8):2429-37. doi:10.1002/art.34428; Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013 Oct;52(10):1809-17. doi:10.1093/rheumatology/ket224. Epub 2013 Jun 27.; Semb AG, Kvien TK, Aastveit AH. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis. 2010;69:1996-2001. doi:10.1136/ard.2009.126128; Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78:179-83. doi:10.1016/j.jbspin.2010.07.016; Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012 Sep;71(9):1524-9. doi:10.1136/annrheumdis-2011-200726; Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005 Feb;52(2):402-11. doi:10.1002/art.20853; Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(2):131-5.; Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010 Dec;268(6):578-85. doi:10.1111/j.1365-2796.2010.02260.x; Rollefstad S, Ikdahl E, Hisdal J, et al. Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases. Front Med (Lausanne). 2015 Nov 10;2:80. doi:10.3389/fmed.2015.00080. eCollection 2015.; Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007 May;34(5):937-42. Epub 2007 Mar 15.; Karpouzas GA, Malpeso J, Choi TY, et al. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis. 2014 Oct;73(10):1797-804.; Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015 Feb 21;36(8):482-9c. doi:10.1093/eurheartj/ehu403. Epub 2014 Nov 27.; Ostrom MP, Gopal A, Ahmadi N, et al. Mortality incidence and the severity of coronary atherosclerosis assessed by computed tomography angiography. J Am Coll Cardiol. 2008 Oct 14;52(16):1335-43. doi:10.1016/j.jacc.2008.07.027; Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol. 2011 Aug 16;58(8):849-60. doi:10.1016/j.jacc.2011.02.074; Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994 Dec;90(6):2645-57.; Ni H, Coady S, Rosamond W, et al. Trends from 1987 to 2004 in sudden death due to coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2009;157:46-52. doi:10.1016/j.ahj.2008.08.016; Sidney S, Rosamond WD, Howard VJ, Luepker RV. The «heart disease and stroke statistics – 2013 update» and the need for a national cardiovascular surveillance system. Circulation. 2013;127:21. doi:10.1161/CIRCULATIONAHA.112.155911; Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics – 2014 update: a report from the American heart association. Circulation. 2014;129:e28-292. doi:10.1161/01.cir.0000442015.53336.12; Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000 Jul 22;356(9226):279-84.; Chang CC, Chang ML, Huang CH, et al. Carotid intima-media thickness and plaque occurrence in predicting stable angiographic coronary artery disease. Сlin Interv Aging. 2013;8:1283-8.; Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veteran's affairs HDL Intervention trial. Aterioscler Throm Vasc Biol. 2005;25:2185-21. doi:10.1161/01.ATV.0000183727.90611.4f; Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28:575-9. doi:10.1161/ATVBAHA.107.157123; Watanabe H, Soderlund S, Soro-Paavonen A, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol. 2006;26:897-902. doi:10.1161/01.ATV.0000209577.04246.c0; Williams PT, Feldman DE. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis. 2011 Jan;214(1):196-202. doi:10.1016/j.atherosclerosis.2010.10.024. Epub 2010 Oct 23.; Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012 Nov-Dec;6(6):496-523.; Arts E, Fransen J, Lemmers H, et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther. 2012 May 14;14(3):R116. doi:10.1186/ar3842; Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct;60(10):2870-9. doi:10.1002/art.24802; Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012 Jul;71(7):1157-62. doi:10.1136/annrheumdis-2011-200493. Epub 2012 Jan 20.; Удачкина ЕВ, Новикова ДС, Попкова ТВ и др. Динамика липидных параметров крови у больных ранним ревматоидным артритом на фоне противоревматической терапии, проводимой по принципу «Лечение до достижения цели» (по данным 18-месячного наблюдения) Научно-практическая ревматология. 2016;54(2):164-70 [Udachkina EV, Novikova DS, Popkova TV, et al. Time course of changes in blood lipid parameters in patients with early rheumatoid arthritis during Treat-To-Target antirheumatic therapy: According to 18-month follow-up findings. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):164-70 (In Russ.)]. doi:10.14412/1995-4484-2016-164-170; Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758-67.; Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001 May 8;103(18):2283-8. doi:10.1161/01.CIR.103.18.2283
-
13Academic Journal
Authors: Олесеюк, А. А., Шепелевич, А. Н.
Subject Terms: атеросклеротическое поражение
Relation: Олесеюк, А. А. Атеросклеротическое поражение сосудистых бассейнов при сердечно-сосудистых катастрофах в анамнезе [Электронный ресурс] / А. А. Олесеюк, А. Н. Шепелевич // Проблемы и перспективы развития современной медицины : сб. науч. ст. XIV Респ. науч.-практ. конф. с междунар. участием студентов и молодых ученых, Гомель, 5–6 мая 2022 г. : в 6 т. / Гомел. гос. мед. ун-т; редкол. : И. О. Стома [и др. ]. – Гомель : ГомГМУ, 2022. – Т. 1. – C. 186–188. – 1 электрон. опт. диск (CD-ROM). Научные руководители: старший преподаватель С. Г. Сейфидинова; к.м.н. А. А. Печенкин; http://elib.gsmu.by/handle/GomSMU/11723
Availability: http://elib.gsmu.by/handle/GomSMU/11723
-
14Academic Journal
Authors: Саричев, Леонід Петрович, Пустовойт, Ганна Леонідівна, Саричев, Ярослав Володимирович, Сарычев, Леонид Петрович, Пустовойт, Анна Леонидовна, Сарычев, Ярослав Владимирович, Sarychev, L. P., Pustovoyt, A. L., Sarychev, Y. V.
Subject Terms: комплекс інтима–медіа, ендотеліальна дисфункція, атеросклеротичне ураження судин, віковий андрогенний дефіцит у чоловіків, комплекс интима–медиа, эндотелиальная дисфункция, атеросклеротическое поражение сосудов, возрастной андрогенный дефицит у мужчин, complex intima–media, endothelial dysfunction, atherosclerotic vascular disease, androgen deficiency of ageing males
File Description: application/pdf
Relation: Саричев Л. П. Інформативність комплексу інтима–медіа як маркера ендотеліальної дисфункції при віковому андрогенному дефіциті у чоловіків / Л. П. Саричев, Г. Л. Пустовойт, Я. В. Саричев // Здоровье мужчины. — 2014. — №2. — С. 126—128.; УДК 616.69 07; https://repository.pdmu.edu.ua/handle/123456789/3900
Availability: https://repository.pdmu.edu.ua/handle/123456789/3900
-
15Academic Journal
-
16Academic Journal
Authors: Вардиков, Д., Яковлева, Е.
Subject Terms: МУЛЬТИСПИРАЛЬНАЯ КОМПЬЮТЕРНОТОМОГРАФИЧЕСКАЯ КОРОНАРОГРАФИЯ, АТЕРОСКЛЕРОТИЧЕСКОЕ ПОРАЖЕНИЕ КОРОНАРНЫХ АРТЕРИЙ, СТЕНТИРОВАНИЕ
File Description: text/html
-
17Academic Journal
Authors: Довгаль, Г., Шевченко, І.
File Description: text/html
-
18Academic Journal
Authors: Пушко, Д., Ганиев, Ф., Габбасов, Э., Гиниятуллин, С., Усков, А., Захаров, О.
File Description: text/html
-
19Academic Journal
Authors: Акчурин, Р., Имаев, Т., Покидкин, Илья, Османов, М., Лепилин, П., Колегаев, А., Марголина, А., Комлев, А.
File Description: text/html
-
20Academic Journal
Authors: БОГАТЫРЁВ В.Г., МАРИНЧУК А.Т., НИКИТИНА К.Е.
File Description: text/html
